[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614365":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":48,"collaborators":10,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":69,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Consorci Sanitari de l'Alt Penedès i Garraf","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Anticoagulant therapy",null,"Patients who has been discharged from hospital with anticoagulant therapy",[13],"Other: Antithrombotic therapy",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Antithrombotic therapy","Anticoagulant treatment prescribed at discharge from an acute care unit",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Mar Saavedra","CONTACT","0034938960025","msaavedra@csapg.cat",{"name":26,"role":22,"phone":23,"phoneExt":27,"email":28},"Noemí Casaponsa","43197","recerca@csapg.cat",[30],{"facility":31,"status":10,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Hospital de Vilafranca","Vilafranca del Penedès","Barcelona","08720","Spain","ES",{"type":38,"coordinates":39},"Point",[40,41],1.69713,41.34618,{"lat":41,"lon":40},[44,45,46],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"name":26,"role":22,"phone":23,"phoneExt":27,"email":28},{"name":21,"role":47,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100614365",false,"NCT07278648","High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department","Prescription of High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department. Retrospective Cohort Study","Inclusion Criteria:\n\n* Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:\n\nB01AA - Vitamin K antagonists: warfarin and acenocoumarol\n\nB01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …\n\nB01AE - Direct thrombin inhibitors: dabigatran\n\nB01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban\n\nExclusion Criteria:\n\n* Those who are not part of the CSAPG healthcare area.\n* Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.","ALL","18 Years",{"count":59,"type":60},150,"ESTIMATED","OBSERVATIONAL","This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.",[64],"Acute Disease",[66,67,68],"Antithrombotic Treatment","Hemorragic Event","Anticoagulants","NOT_YET_RECRUITING","2025-12-18",{"date":72,"type":73},"2025-12-24","ACTUAL",{"date":75,"type":60},"2026-02-05",{"date":77,"type":60},"2026-03-01",{"name":5,"class":6},1]